Memorial Sloan Kettering Cancer Center, New York City

Mark Robson, MD serves as Chief of the Breast Medicine Service and is the former Clinic Director of the Clinical Cancer Genetic Service, in the Department of Medicine at Memorial Sloan Kettering Cancer Center. He is also Professor of Medicine at Weill Cornell Medical College. He received his B.Sc. from Washington and Lee University and his M.D. from the University of Virginia. He performed residency and fellowship training at Walter Reed Army Medical center before coming to Memorial Sloan-Kettering in 1996. He serves on the Cancer Prevention and Ethics Committees of ASCO, is an Associate Editor for JNCI and is on the editorial board of the Journal of Clinical Oncology. Dr. Robson’s research is primarily directed toward the improving the integration of genetic information into the clinical management of women with breast cancer. He and his colleagues have conducted a number of studies examining outcomes in women with hereditary breast cancer to better define the risks and benefits of treatments such as breast conserving therapy and adjuvant chemotherapy in this group. He is also coordinating studies of PARP inhibitors in women with BRCA mutation-associated breast cancer. He and his coworkers have also conducted a number of studies examining the effectiveness of screening interventions such as breast MRI or ovarian cancer screening in women at hereditary risk. He is also investigating the optimal integration of new genetic technologies, such as genomic profiling and multi-gene testing, into the care of women at risk for breast cancer.